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The conventional ‘Warburg eff  ect’ versus oxidative 
mitochondrial metabolism
Th   e Warburg eﬀ  ect, also known as aerobic glycolysis, is 
deﬁ  ned as the propensity of cancer cells to take up high 
levels of glucose and to secrete lactate in the presence of 
oxygen. Warburg’s original work indicated that while 
glucose uptake and lactate production are greatly 
elevated, a cancer cell’s rate of mitochondrial respiration 
is similar to that of normal cells [1,2]. He, however, 
described it as a ‘respiratory impairment’ due to the fact 
that, in cancer cells, mitochondrial respiration is smaller, 
relative to their glycolytic power, but not smaller relative 
to normal cells. He recognized that oxygen consumption 
is not diminished in tumor cells, but that respiration is 
disturbed because glycolysis persists in the presence of 
oxygen [1,2]. Unfortunately, the perception of his original 
ﬁ  ndings was simpliﬁ  ed over the years, and most subse-
quent papers validated that cancer cells undergo aerobic 
glycolysis and produce lactate, but did not measure 
mitochondrial respiration, and just presumed decreased 
tricarboxylic acid (TCA) cycle activity and reduced 
oxida  tive phosphorylation [1,2]. It is indeed well docu-
mented that, as a consequence of intra-tumoral hypoxia, 
the hypoxia-inducible factor (HIF)1α pathway is activated 
in many tumors cells, resulting in the direct up-regulation 
of lactate dehydrogenase (LDH) and increased glucose 
consumption. For updated reviews on the Warburg 
eﬀ  ect, the reader is encouraged to refer to the following 
papers [3,4].
However, new ﬁ   ndings compel us to reconsider the 
current model of cancer cell metabolism. First, not all 
tumors are associated with increased aerobic glycolysis, 
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© 2011 BioMed Central Ltdand in fact it is now clear that cancer cells utilize both 
glycolysis and oxidative phosphorylation to satisfy their 
metabolic needs. Experimental assessments of ATP pro-
duc  tion in cancer cells have demonstrated that oxidative 
pathways play a signiﬁ  cant role in energy generation, and 
may be responsible for about 50 to 80% of the ATP 
generated [5-8]. Also, it should be considered that most 
studies were performed using isolated cancer cells, which 
may behave very diﬀ  erently from cancer cells in vivo, sur-
roun  ded by their natural microenvironment [9] (see also 
Koukourakis and colleagues [10] for another viewpoint).
Second, several studies now clearly indicate that mito-
chondrial activity and oxidative phosphorylation support 
tumor growth. Loss-of-function mutations in the TCA 
cycle gene IDH1 (isocitrate dehydrogenase 1) are found 
in about 70% of gliomas, but, interestingly, correlate with 
a better prognosis and improved survival, suggesting that 
severely decreased activity in one of the TCA cycle 
enzymes does not favor tumor aggressiveness [11]. Th  e 
mitochondrial protein p32 was shown to maintain high 
levels of oxidative phosphorylation in human cancer cells 
and to sustain tumorigenicity in vivo [12]. In addition, 
STAT3 is known to enhance tumor growth and to predict 
poor prognosis in human cancers [13]. Interestingly, a 
pool of STAT3 localizes to the mitochondria, to sustain 
high levels of mitochondrial respiration [14] and to 
augment transformation by oncogenic Ras [15,16]. Simi-
larly, the mitochondrial transcription factor A (TFAM), 
which is required for mitochondrial DNA replication and 
oxidative phosphorylation, is also required for K-Ras-
induced lung tumorigenesis [17]. Finally, when con-
strained to use glycolysis by depletion of mitochondrial 
DNA, melanoma B16 cells (B16ρ0) and breast cancer 
T47D cells (T47Dρ0), show severe impairment of tumori-
genicity in vivo [18,19].
Th  ere is also evidence that pro-oncogenic molecules 
regulate mitochondrial function. Cyclin D1 inhibits mito-
chondrial function in breast cancer cells [20]. Over-
expression of cyclin D1 is observed in about 50% of 
invasive breast cancers and is associated with a good 
clinical outcome [21], indicating that inhibition of mito-
chondrial activity correlates with favorable prognosis. 
Importantly, it was shown that the oncogene c-Myc 
stimulates mitochondrial biogenesis, and enhances gluta-
mine metabolism by regulating the expression of mito-
chondrial glutaminase, the ﬁ  rst enzyme in the glutamine 
utilization pathway [22]. Glutamine is an essential 
metabolic fuel that is converted to alpha-ketoglutarate 
and serves as a substrate for the TCA cycle or for 
glutathione synthesis, to promote energy production and 
cellular biosynthesis, and to protect against oxidative 
stress [23]. Interestingly, pharmacological targeting of 
mito  chondrial glutaminase inhibits cancer cell trans-
form  ing activity, suggesting that glutamine metabolism 
and its role in fueling and replenishing the TCA cycle are 
required for neoplastic transformation [24] (for a recent 
review on glutamine cancer metabolism, see [2]).
The reverse Warburg eff  ect
It is increasingly apparent that the tumor microenviron-
ment regulates neoplastic growth and progression. 
Activation of the stroma is a critical step required for 
tumor formation. Among the stromal players, cancer 
associated ﬁ  broblasts (CAFs) have recently taken center 
stage [25]. CAFs are activated, contractile ﬁ  broblasts that 
display features of myo-ﬁ   broblasts, express muscle-
speciﬁ  c actin, and show an increased ability to secrete 
and remodel the extracellular matrix [26,27]. Th  ey are 
not just neutral spectators, but actively support malig-
nant transformation [28] and metastasis [29], as com-
pared to normal resting ﬁ  broblasts. For example, in a 
humanized mouse model of breast cancer, oncogenically 
driven human organoids develop tumors only if co-
injected with immortalized ﬁ   broblasts and not with 
normal primary ﬁ   broblasts, suggesting that stromal 
activa  tion is required for breast cancer formation [30].
Importantly, the tumor stroma dictates clinical out-
come and constitutes a source of potential biomarkers 
[31]. Expression proﬁ  ling has identiﬁ  ed a cancer-asso-
ciated stromal signature that predicts good and poor 
clinical prognosis in breast cancer patients, indepen-
dently of other factors [32-34].
We and others have recently shown that a loss of 
caveolin-1 (Cav-1) in the stromal compartment is a novel 
biomarker for predicting poor clinical outcome in all of the 
most common subtypes of human breast cancer, including 
the more lethal triple negative subtype [35,36]. A loss of 
stromal Cav-1 predicts early tumor recurrence, lymph-
node metastasis, tamoxifen-resistance, and poor survival. 
Overall, breast cancer patients with a loss of stromal Cav-1 
show a 20% 5-year survival rate, compared to the 80% 
5-year survival of patients with high stromal Cav-1 
expression. In triple negative patients, the 5-year survival 
rate is 75.5% for high stromal Cav-1 versus 9.4% for absent 
stromal Cav-1 [37]. A loss of stromal Cav-1 also predicts 
progression to invasive disease in ductal carcinoma in situ 
patients, suggesting that a loss of Cav-1 regulates tumor 
progression [35]. Similarly, a loss of stromal Cav-1 is 
associated with advanced disease and metastasis, as well as 
a high Gleason score, in prostate cancer patients [38].
In order to mechanistically dissect how a loss of 
stromal Cav-1 induces a lethal microenvironment, we 
have employed Cav-1(-/-) null mice as a model system. 
Complementary studies were also performed with a co-
culture model of normal human ﬁ  broblasts and MCF7 
breast cancer cells.
Unbiased proteomic and transcriptional analysis has 
shown that Cav-1(-/-) null bone-marrow-derived stromal 
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markers and glycolytic enzymes, clearly indicating that a 
loss of Cav-1 promotes myo-ﬁ  broblast conversion and 
induces aerobic glycolysis in stromal cells [39]. Th  us, 
stromal cells lacking Cav-1 undergo aerobic glycolysis 
and secrete energy-rich metabolites (such as lactate and 
pyruvate) that directly feed cancer cells and fuel mito-
chondrial respiration of adjacent cancer cells. We have 
termed this novel hypothesis the ‘reverse Warburg eﬀ  ect’ . 
Th  is novel idea has now also been independently 
conﬁ  rmed by Pol and colleagues [40], who demonstrated 
that genetic ablation of Cav-1 in murine ﬁ  broblasts is 
indeed suﬃ     cient to functionally induce the onset of 
aerobic glycolysis via mitochondrial dysfunction [40]. 
Interestingly, immunohistochemistry on human breast 
cancers lacking stromal Cav-1 has demonstrated the 
over-expression of key glycolytic enzymes, such as PKM2 
and LDH, in the ﬁ  broblastic tumor stroma [39].
In further support of this hypothesis, co-culture with 
cancer cells promotes Cav-1 down-regulation in adjacent 
ﬁ  broblasts. Importantly, when cultured under homotypic 
conditions, MCF7 cancer cells have a very low mito  chon-
drial mass (the conventional Warburg eﬀ  ect). However, 
co-culture with ﬁ  broblasts, which more closely mirrors 
the microenvironment of a naturally occurring tumor, 
promotes a very signiﬁ   cant increase in mitochondrial 
mass in MCF7 cancer cells, suggesting that the Warburg 
eﬀ   ect might be an in vitro artifact [41]. Importantly, 
lactate administration to homotypic MCF7 cancer cell 
cultures signiﬁ   cantly increases mitochondrial mass, 
suggesting that lactate administration phenocopies the 
presence of reactive ﬁ   broblasts [41], by promoting 
mitochondrial biogenesis. Th  ese new data indicate that 
cancer cells and CAFs develop a ‘symbiotic’ or ‘parasitic’ 
relationship, with the vectorial and unilateral transfer of 
energy from glycolytic stromal cells to oxidative cancer 
cells (Figures 1 and 2).
Clinically, high glucose uptake has been exploited to 
monitor tumor growth using position emission tomo-
graphy (PET) scanning via radiolabeled 2-deoxy-glucose. 
However, we should acknowledge that PET avidity does 
not necessarily correlate with high aerobic glycolysis. For 
example, PET is not useful in clear cell renal carcinomas 
[42,43], which are the tumor ‘prototype’ in which the 
Warburg eﬀ  ect should sustain tumor formation. About 
half of clear cell renal carcinomas are due to mutations in 
the Von Hippel-Lindau (VHL) gene [44,45], leading to 
HIF1α constitutive activation and forced induction of 
aerobic glycolysis [46-48]. Conversely, little attention is 
paid to understanding which cell-type or compartments 
within a tumor are most PET avid. In fact, the clinical use 
of PET is well established in Hodgkin’s lymphomas [49], 
which are composed of less than 10% tumor cells, the rest 
being stromal and inﬂ  ammatory cells [50]. Yet, Hodgkin’s 
lymphomas are very PET avid tumors, suggesting that 
2-deoxy-glucose uptake may be associated with the 
tumor stroma. Th  at the ﬁ   brotic component may be 
glucose avid is further supported by the notion that PET 
is clinically used to assess the therapeutic response in 
gastrointestinal stromal tumors (GIST), which are a 
subset of tumors of mesenchymal origin. Finally, pilot 
clinical studies have shown that PET is useful for 
detection of various forms of ﬁ  brosis, including pulmo-
nary ﬁ  brosis [51].
Th  e reverse Warburg eﬀ  ect can also be described as 
‘metabolic coupling’ between supporting glycolytic stromal 
cells and oxidative tumor cells. Metabolic cooperativity 
between adjacent cell-compartments is observed in 
several normal physiological settings. During folliculo-
genesis and early embryogenesis, oocytes are surrounded 
by supporting cumulus granulosa (CG) cells. Oocytes 
lack some crucial metabolic functions, such as the ability 
to utilize glucose, to produce cholesterol and to transport 
certain amino acids. Th  us, oocytes control CG cell 
metabolism, promoting their glycolysis, cholesterol 
synthesis and amino acid uptake [52,53]. Remarkably, 
both oocytes and zygotes can reach a two-cell stage only 
in the presence of pyruvate and oxalo  acetate, but not 
using glucose [54,55]. However, upon co-culture with CG 
cells, oocytes or zygotes can cleave to a two-cell stage 
also in the presence of glucose, clearly indicating that CG 
cells metabolize glucose and supply the oocyte with the 
Figure 1. The autophagic tumor stroma model of cancer 
metabolism. Cancer cells induce oxidative stress in adjacent 
cancer-associated fi  broblasts (CAFs). This activates reactive oxygen 
species (ROS) production and autophagy. ROS production in CAFs, 
via the bystander eff  ect, serves to induce random mutagenesis in 
epithelial cancer cells, leading to double-strand DNA breaks and 
aneuploidy. Cancer cells mount an anti-oxidant defense and up-
regulate molecules that protect them against ROS and autophagy, 
preventing them from undergoing apoptosis. So, stromal fi  broblasts 
conveniently feed and mutagenize cancer cells, while protecting 
them against death. See the text for more details. A+, autophagy 
positive; A-, autophagy negative; AR, autophagy resistant.
A+ A- or AR
Oxidative
Stress
1. Recycled Nutrients
2. Random Mutagenesis
3. Protection Against Apoptosis
Stromal
Fibroblasts
(CAFs)
Cancer
Cells
Sotgia et al. Breast Cancer Research 2011, 13:213
http://breast-cancer-research.com/content/13/4/213
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this regard, transcriptional proﬁ   ling of CG cells and 
oocytes has revealed that key enzymes of the glycolytic 
pathway (aldolase A, enolase 1, LDHA, and PKM2) are 
very highly expressed in CG cells, but are undetectable in 
oocytes [56]. Th  ese results indicate that granulosa cells 
support the development and maturation of oocytes and 
early embryos by providing them with essential nutrients, 
such as oxidative phosphorylation substrates (pyruvate 
and lactate [57]), amino acids [58], and cholesterol [59].
Metabolic coupling is also normally observed in the 
brain between astrocytes and neurons, and this is known 
as ‘neuron-glia metabolic coupling’ [60,61]. In this 
regard, glycolytic astrocytes generate high levels of 
lactate to support mitochondrial oxidative phosphory-
lation in adjacent neurons. Consistent with this idea, 
LDH is preferentially expressed in astrocytes, and the 
mitochondrial enzyme pyruvate dehydrogenase is pre  sent 
selectively within the neurons [62,63]. Also, in skeletal 
muscle it is well established that glycolytic fast-twitch 
muscle ﬁ  bers produce lactate, which is then secreted via 
monocarboxylate transporter (MCT) 4. Lactate is then 
taken up by the slow-twitch ﬁ  bers expressing MCT1 and 
utilized as a substrate for oxidative phosphorylation 
[64,65]. Th   is form of metabolic coupling is known as the 
‘skeletal muscle lactate shuttle’ [66].
As such, it is perhaps not surprising that tumors may 
have also developed a form of metabolic coupling, 
speciﬁ   cally involving tumor-stromal interactions. In 
further support of the existence of a ‘lactate shuttle’ in 
human tumors, we have now shown that CAFs express 
MCT4 (for lactate extrusion), while breast cancer cells 
express MCT1 (for lactate uptake) (Figure 3) [67]. 
Interestingly, MCT4 expression in CAFs is induced by 
oxidative stress, and MCT4 is a known HIF1α target gene 
(see Discussion below) [67].
Figure 2. The reverse Warburg eff  ect. (a) Via oxidative stress, cancer cells activate two major transcription factors in adjacent stromal fi  broblasts 
(hypoxia-inducible factor (HIF)1α and NFκB). This leads to the onset of both autophagy and mitophagy, as well as aerobic glycolysis, which then 
produces recycled nutrients (such as lactate, ketones, and glutamine). These high-energy chemical building blocks can then be transferred and 
used as fuel in the tricarboxylic acid cycle (TCA) in adjacent cancer cells. The outcome is high ATP production in cancer cells, and protection 
against cell death. ROS, reactive oxygen species. (b) Homotypic cultures (upper panels) of MCF7 cells (right) and hTERT-fi  broblasts (left) were 
immunostained with a mitochondrial membrane antibody (red). Note that mitochondrial mass is lower in mono-cultures of MCF7 cells compared 
to fi  broblasts. However, co-culture of MCF7 cells with fi  broblasts (lower panel) induces a dramatic increase in mitochondrial mass in the ‘central 
MCF7 cell colony’, outlined by the dotted white oval. In contrast, mitochondrial mass is decreased in co-cultured fi  broblasts. Panel (b) was modifi  ed 
and reproduced with permission from [41,78].
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protection against cell death
Recent studies have dissected the mechanism(s) by which 
a loss of stromal Cav-1 leads to an aggressive breast 
cancer phenotype, and have shown that oxidative stress 
plays a central role. Th  e role of oxidative stress in sus-
taining tumor growth is underscored by the observation 
that reactive oxygen species (ROS)-mediated myo-ﬁ  bro-
blast conversion is suﬃ   cient to reduce tumor-free sur-
vival, and increases metastatic potential in a mammary 
tumor mouse model [68].
Gene expression proﬁ   ling of Cav-1(-/-) null bone-
marrow-derived stromal cells has shown the up-
regulation of gene transcripts associated with ROS pro-
duc  tion, and over-expression of the transcriptional targets 
of HIF1α and NFκB, suggesting that a loss of stromal 
Cav-1 induces oxidative stress, mimics hypoxia, and 
stimulates inﬂ  ammation [41].
Co-cu    ltures of normal human ﬁ  broblasts and MCF7 
cells indicate that cancer cells use oxidative stress as a 
weapon to trigger the conversion of adjacent ﬁ  broblasts 
into myo-ﬁ  broblasts [69]. Cancer cell-induced oxidative 
Figure 3. Evidence supporting a ‘lactate shuttle’ in human tumors: compartmentalized distribution of monocarboxylate transporter 
(MCT)1/4. (a) MCT4 is expressed in the fi  broblastic stromal compartment of human breast cancers. Note that MCT4 staining is absent from the 
tumor epithelial cells, but is present in the surrounding stroma. MCT4 staining outlines the cancer-associated fi  broblasts that surround nests of 
epithelial cancer cells. (b) MCT1 is expressed in the epithelial compartment of human breast cancers. Note that MCT1 staining is present in the 
tumor epithelial cells, but is absent in the surrounding stroma. (c) The lactate shuttle: an energy transfer mechanism in normal tissue and human 
cancers. MCT4 functions primarily as a transporter that extrudes lactate from cells that are undergoing aerobic glycolysis and lack functional 
mitochondria. After lactate is extruded by MCT4 in cancer-associated fi  broblasts (CAFs), lactate is then taken up by MCT1 in adjacent cancer cells. 
Similarly, ketones are transported by the same MCTs that handle lactate. Our studies suggest that metabolic coupling occurs between CAFs and 
adjacent tumor cells. Modifi  ed and reproduced with permission from [67].
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blasts, induces the lysosomal-mediated degradation of 
Cav-1, and promotes mitochondrial dysfunction, result-
ing in increased aerobic glycolysis [41]. In turn, these 
glycolytic ﬁ  broblasts support tumor cell mitochondrial 
respiration and growth by actively transferring high-
energy nutrients (such as lactate and pyruvate) to cancer 
cells.
In support of the ‘reverse Warburg eﬀ  ect’, comparison 
of the tumor-promoting properties of two ﬁ  broblast lines 
(named CL3 and CL4) with either mitochondrial or 
glycolytic metabolism has revealed that aerobic glycolysis 
in CAFs greatly promotes tumor formation. CL3 ﬁ  bro-
blasts show oxidative metabolism and increased mito-
chon  drial mass, whereas CL4 ﬁ  broblasts display a shift 
towards aerobic glycolysis and increased lactate produc-
tion [70]. Interestingly, in a xenograft model, CL4 ﬁ  bro-
blasts enhance the growth of mammary tumors by 
approxi  mately eight-fold compared to CL3 cells, without 
a detectable increase in angiogenesis. Consistent with this 
growth-promoting eﬀ  ect, CL4 ﬁ  broblasts also increase the 
mitochondrial mass of co-cultured breast cancer cells [71].
An oxidative-stress-rich micro-environment generates 
DNA damage in both cancer and stromal cells (Figure 1). 
We have shown that MCF7 cancer cells induce oxidative 
stress and promote DNA double-strand breaks in 
associated stromal cells, which are blocked by anti-
oxidant treatments [41]. Similarly, after three-dimen-
sional co-culture with prostate cancer cells, bone-derived 
stromal cells undergo stable cytogenetic modiﬁ  cations by 
a ROS-mediated mechanism [72].
Conversely, in an MCF7-ﬁ  broblast co-culture model, 
MCF7 cancer cells undergo aneuploidy and random 
muta  genesis [41], suggesting that CAFs facilitate the 
dynamic search for a more aggressive ‘mutator pheno-
type’ in cancer cells (Figure 1). Functionally, ﬁ  broblasts 
provide cancer cells with a six-fold protection against cell 
death [41] (Figure 2), via the up-regulation of the anti-
apoptotic protein TIGAR [41]. Cav-1 knockdown ﬁ  bro-
blasts provide even greater protection for cancer cells 
against apoptosis, clearly indicating that a loss of stromal 
Cav-1 in humans may greatly facilitate tumor growth by 
suppression of cancer cell death [41].
Th  us, data supporting the ‘reverse Warburg eﬀ  ect’ 
indicate that cancer cells and ﬁ  broblasts are metabolically 
coupled and mutagenically co-evolving [41,73]. Cancer 
cells use oxidative stress to corrupt adjacent ﬁ  broblasts 
and to induce their metabolic re-programming [73]. In 
this way, ﬁ  broblasts secrete energy rich metabolites that 
facilitate cancer cell survival. In addition, ﬁ  broblasts 
promote mutagenesis of cancer cells, leading to a more 
aggressive ‘aneuploid’ phenotype [41,73]. Aneuploidy in 
cancer cells is known to be associated with poor clinical 
outcome.
Hypoxia, autophagy, and mitophagy in the tumor 
stroma
Metabolomic proﬁ  ling reveals that Cav-1(-/-) null mam-
mary fat pads display a highly catabolic metabolism, with 
the increased release of several metabolites, such as 
amino acids, ribose and nucleotides, and a shift towards 
gluconeogenesis, as well as mitochondrial dysfunction 
[74]. Th  ese changes are consistent with increased auto-
phagy, mitophagy and aerobic glycolysis, all processes 
that are induced by oxidative stress [74]. Autophagy or 
‘self-eating’ is the process by which cells degrade their 
own cellular components to survive during starvation or 
to eliminate damaged organelles after oxidative stress. 
Mitophagy, or mitochondrial-autophagy, is particularly 
important to remove damaged ROS-generating 
mitochondria.
An autophagy/mitophagy program is also triggered by 
hypoxia [75,76]. Hypoxia is a common feature of solid 
tumors, and promotes cancer progression, invasion and 
metastasis [77]. Interestingly, via induction of autophagy, 
hypoxia is suﬃ   cient to induce a dramatic loss of Cav-1 in 
ﬁ  broblasts. Th  e hypoxia-induced loss of Cav-1 can be 
inhibited by the autophagy inhibitor chloroquine, or by 
pharmacological inhibition of HIF1α [69,78]. Conversely, 
small interfering RNA-mediated Cav-1 knock-down is 
suﬃ     cient to induce pseudo-hypoxia, with HIF1α and 
NFκB activation, and to promote autophagy/mitophagy, 
as well as a loss of mitochondrial membrane potential in 
stromal cells [78]. Th  ese results indicate that a loss of 
stromal Cav-1 is a marker of hypoxia and oxidative stress. 
In a co-culture model, autophagy in cancer-associated 
ﬁ  broblasts was shown to promote tumor cell survival via 
the induction of the pro-autophagic HIF1α and NFκB 
pathways in the tumor stromal microenvironment [78]. 
Finally, the mitophagy marker Bnip3L is selectively up-
regulated in the stroma of human breast cancers lacking 
Cav-1, but is notably absent from the adjacent breast 
cancer epithelial cells [78].
Another study has shown that cell-speciﬁ  c induction of 
autophagy by HIF1α activation in ﬁ  broblasts or MDA-
MB-231 cells diﬀ  erentially  aﬀ   ects tumor growth. In a 
xenograft model, HIF1α activation in ﬁ  broblasts greatly 
enhances the tumorigenicity of co-injected MDA-MB-231 
cells, whereas HIF1α activation in MDA-MB-231 cancer 
cells suppresses tumor growth [79]. Importantly, in this 
experimental setting, the levels of tumor angiogenesis 
were unchanged. As HIF1α triggers autophagy in both 
ﬁ  broblasts and cancer cells, these data demonstrate that 
the role of autophagy in driving tumor formation is cell-
type speciﬁ  c, and that stromal autophagy, and not cancer 
cell autophagy, favors tumor growth.
Several studies have demonstrated that the over-
expression of autophagic markers, such as ATG16L and 
cathepsin K and D, in the stroma and not in tumor cells 
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phagic markers, such as Beclin 1, in tumor cells correlates 
with poor clinical outcome, suggesting that activation of 
an autophagic program in tumor cells reduces tumor 
aggressiveness [83].
Metabolome proﬁ  ling of several types of human cancer 
tissues versus corresponding normal tissues have consis-
tently shown that cancer tissues are highly catabolic, with 
the signiﬁ  cant accumulation of many amino acids and 
TCA cycle metabolites [84,85]. Th  e levels of reduced 
glutathione were decreased in primary and metastatic 
prostate cancers compared to benign adjacent prostate 
tissue, suggesting that aggressive disease is associated 
with increased oxidative stress [86]. Also, these data 
show that the tumor microenvironment has increased 
oxidative-stress-induced autophagy and increased 
catabolism.
Taken together, all these ﬁ  ndings suggest an integrated 
model whereby a loss of stromal Cav-1 induces autophagy/
mitophagy in the tumor stroma, via oxidative stress. Th  is 
creates a catabolic micro-environment with the local 
accumulation of chemical building blocks and recycled 
nutrients (such as amino acids and nucleotides), directly 
feeding cancer cells to sustain their survival and growth. 
We have termed this novel idea the ‘autophagic tumor 
stroma model of cancer’ [74]. Th  is new paradigm may 
explain the ‘autophagy paradox’, which is based on the 
fact that both the systemic inhibition and systemic 
stimulation of autophagy prevent tumor formation [87]. 
We propose that vectorial energy transfer from the tumor 
stroma to cancer cells directly sustains tumor growth, 
and that interruption of such metabolic coupling will 
block tumor growth. Autophagy inhibitors (such as 
chloroquine) functionally block the catabolic transfer of 
metabolites from the stroma to the tumor, inducing 
cancer cell starvation and death [88]. Conversely, 
autophagy inducers (such as rapamycin) promote 
autophagy in tumor cells and induce cell death [89]. Th  us, 
both inhibitors and inducers of autophagy will have a 
similar eﬀ  ect by severing the metabolic coupling of the 
stroma and tumor cells, resulting in tumor growth 
inhibition (cutting ‘oﬀ  ’ the fuel supply).
Th   is model may also explain why enthusiasm for anti-
angiogenic therapy has been dampened. In most cases, 
the clinical beneﬁ  ts are short term, and more importantly, 
new data suggest an unexpected link between anti-angio-
genic treatments and metastasis. In pre-clinical models, 
anti-vascular endothelial growth factor (anti-VEGF) 
drugs (sunitinib and anti-VEGFR2 blocking antibodies) 
were shown to inhibit localized tumor formation, but 
potently induced relapse and metastasis [90-92]. Th  us,  by 
inducing hypoxia in the tumor microenvironment, anti-
angiogenic drugs may create a more favorable metastatic 
niche [93]. Hypoxia-induced autophagy may play a role 
by generat  ing a catabolic micro-environment rich in 
chemical building blocks that can be directly used by 
cancer cells to sustain malignant transformation and 
metastatic progression.
Finally, the autophagic tumor stroma model can also 
provide an explanation for systemic cachexia, which is 
progressive skeletal muscle and adipose tissue wasting, 
aﬀ  ecting up to 50% of all cancer patients and resulting in 
severe weight loss and shortened survival [94]. Cachexia 
is the result of increased energy consumption and higher 
metabolic rates [95]. Based on our data, we envision that 
cancer leads to a generalized catabolic state via an 
autophagic-mechanism that generates building blocks 
and starves the rest of the body. While the exact signaling 
pathways governing this phenomenon are not yet fully 
elucidated, it is clear that oxidative stress-induced auto-
phagy functions as a driver of muscle wasting [96]. For 
example, skeletal muscles from tumor-bearing mice 
showed impaired Akt activation and a more than 50-fold 
induction of Bnip3, a well recognized marker of 
autophagy/mitophagy [97]. Th  ese ﬁ   ndings also help 
explain why patients with metabolic syndrome and 
diabetes have an increased risk for the development of 
multiple epithelial cancers, due to their constitutive and 
systemic activation of the autophagic program, and the 
over-production of high-energy nutrients, such as lactate 
and ketones [74].
We have recently used laser-capture micro-dissection 
of the tumor stroma from human breast cancers to 
directly validate that a loss of stromal Cav-1 is trans-
criptionally associated with oxidative stress, hypoxia, 
autophagy, and mitochondrial dysfunction, via gene-set 
enrichment analysis (Figure 4) [98]. In addition, we see 
that oxidative stress in CAFs induces cytokine production 
via NFκB activation, directly linking inﬂ  ammation with 
autophagy/catabolism in the tumor stroma [99]. So, 
cachexia may start locally as stromal autophagy, and then 
spread systemically via cytokine production and inﬂ  am-
mation, which also drive autophagy [99].
Glutamine utilization, ammonia production, and 
autophagy in the tumor stroma
In direct support that cancer cells use mitochondrial 
oxidative metabolism, many investigators have shown 
that cancer cells are ‘addicted’ to glutamine [24,100]. 
Gluta  mine is a non-essential amino acid that is metabo-
lized to glutamate and enters the TCA cycle as alpha-
ketoglutarate, resulting in high ATP generation via oxida-
tive phosphorylation [2,22,101-103].
Recent studies also show that ammonia is a by-product 
of glutaminolysis [104-106]. In addition, ammonia can 
act as a diﬀ  usible inducer of autophagy [104-106]. Given 
these observations, glutamine addiction in cancer cells 
provides another mechanism for driving and/or 
Sotgia et al. Breast Cancer Research 2011, 13:213
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Page 7 of 13Figure 4. Molecular profi  ling of a Cav-1 defi  cient tumor micro-environment in breast cancer patients. (a) The transcriptional profi  les 
of caveolin-1 (Cav-1)-positive (+) tumor stroma (N = 4) versus Cav-1-negative (-) tumor stroma (N = 7) were compared, via laser-capture 
microdissection. We identifi  ed 238 gene transcripts that were up-regulated and 232 gene transcripts that were down-regulated in the stroma of 
tumors showing a loss of Cav-1 expression. Note that the two patient populations are transcriptionally distinct. (b) The Cav-1-defi  cient stromal gene 
signature is associated with poor survival in estrogen receptor-positive and luminal A breast cancer patients. Note that the Cav-1-defi  cient stromal 
signature is clearly associated with decreased overall survival. (c) Heat maps of the gene transcripts associated with the response to hypoxia, 
glycolysis, and autophagy. Note that Cav-1-defi  cient stroma shows the up-regulation of hypoxia target genes (65 transcripts), glycolysis/pyruvate 
metabolism (15 transcripts), and autophagy (22 transcripts). Modifi  ed and reproduced with permission from [98].
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Page 8 of 13main  tain  ing autophagy in the tumor micro-environment 
(Figure  5). In support of this idea, we have previously 
shown that a loss of Cav-1 in the stroma is suﬃ   cient to 
drive autophagy, resulting in increased glutamine 
produc  tion in the tumor micro-environment [74].
Th   us, this concept deﬁ  nes a new vicious cycle in which 
autophagy in the tumor stroma transfers glutamine to 
cancer cells, and the by-product of this metabolism, 
ammonia, maintains autophagic glutamine production 
(Figure 5). Th   is model ﬁ  ts well with the ‘autophagic tumor 
stroma model of cancer metabolism’, in which energy-
rich recycled nutrients (lactate, ketones, and glutamine) 
fuel oxidative mitochondrial metabolism in cancer cells.
Lessons from other paradigms: an infectious 
parasitic cancer cell that metastasizes and captures 
mitochondrial DNA from host cells
We have recently proposed that cancer cells behave like 
‘parasites’, by inducing oxidative stress in normal host 
ﬁ   broblasts, resulting in the production of recycled 
nutrients via autophagy [41,69,78]. Th  is is exactly the 
same mechanism by which infectious parasites (such as 
malaria) obtain nutrients and are propagated by inducing 
oxidative stress and autophagy in host cells [107-109]. In 
this regard, malaria is an ‘intracellular’ parasite, while 
cancer cells may be thought of as ‘extracellular’ parasites. 
Th   is explains why chloroquine is both an eﬀ  ective anti-
malarial drug and an eﬀ  ective anti-tumor agent, as it 
functions as an autophagy inhibitor [110], cutting oﬀ   the 
‘fuel supply’ in both disease states.
Are there any examples of cancer cells that act as 
infectious parasites? Surprisingly, the answer is yes [111]. 
Th   ere are four known types: canine transmissible 
venereal tumor (CTVT), which is a sexually transmitted 
disease that occurs in feral dogs [112] - it is transmitted 
through coitus, licking/biting, or sniﬃ   ng;  devil  facial 
tumor disease, spread among Tasmanian devils via facial 
biting [113,114]; contagious reticulum cell sarcoma, 
which is transmitted between Syrian hamsters via 
mosquito bites [115,116]; and malignant ﬁ  brous histio-
cytoma, which was transmitted from a cancer patient to 
his surgeon [117] during an injury that occurred when 
the surgeon was operating.
Th  ese parasitic cancers are all transmitted by allo-
grafting, so the cancer cells literally ‘metastasize’ from 
one aﬀ  ected host to another ‘naïve’ host, in an infectious 
manner that does not involve a virus.
Experimentally, the most is known about CTVT. Th  is 
disease is thought to have originated in ancient wolves or 
coyotes, and the tumor cells themselves act as the 
infectious agent. As such, these cancer cells are 
genetically distinct from their hosts, as determined by 
genomic sequence analysis of their nuclear DNA [118]. 
CTVT represents the oldest known cancer cell line that 
has been continuously propagated, most likely for more 
than 10,000 years [118,119].
Interestingly, it has recently been shown that CTVT 
tumor cells survive by periodically ‘capturing’ mito  chon-
drial DNA from their hosts [119,120]. Th   us, it has been 
suggested that these CVCT tumor cells have survived for 
more than 10,000 years by maintaining and renewing 
their capacity for oxidative mitochondrial metabolism by 
‘stealing’ host cell mitochondrial DNA [119,120]. In 
accordance with this idea, CTVT is highly sensitive to 
adriamycin/doxorubicin therapy [121], a chemo-thera  peu  tic 
agent that also functions as a mitochondrial poison.
Similarly, it has been independently shown that human 
cancer cells can ‘steal’ live mitochondria or mitochondrial 
DNA [122] from adjacent mesenchymal stem cells in 
culture, which then rescues aerobic glycolysis in these 
cancer cells [122]. Th  is is known as mitochondrial 
transfer [122]. Interestingly, others have shown that 
metastatic breast cancer cells show the up-regulation of 
numerous mitochondrial proteins [123], speciﬁ  cally 
Figure 5. Glutamine utilization in cancer cells and the tumor 
stroma. Oxidative mitochondrial metabolism of glutamine in cancer 
cells produces ammonia. Ammonia production is suffi   cient to 
induce autophagy. Thus, autophagy in cancer-associated fi  broblasts 
provides cancer cells with an abundant source of glutamine. In turn, 
the ammonia produced maintains the autophagic phenotype of the 
adjacent stromal fi  broblasts. See text for details. TCA, tricarboxylic 
acid.
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Page 9 of 13associated with oxidative phosphorylation, as seen by 
unbiased proteomic analysis [123].
Th  us, increased mitochondrial oxidative metabolism 
may be a key driver of tumor cell metastasis. In further 
support of this argument, treatment of MCF7 cancer 
cells with lactate is indeed suﬃ   cient  to  induce 
mitochondrial biogenesis in these cells [41,78] (Figure 6). 
To determine if these ﬁ  ndings may be clinically relevant, 
a lactate-induced gene signature was recently generated 
using MCF7 cells [124]. Th  is gene signature shows that 
lactate induces ‘stemness’ in cancer cells, and this lactate-
induced gene signature predicts poor clinical outcome 
(including tumor recurrence and metastasis) in breast 
cancer patients [124] (Figure 6). Th  ese ﬁ  ndings  are 
consistent with experiments showing that intraperitoneal 
injection of lactate in an MDA-MB-231 xenograft model 
results in an approximately ten-fold increase in lung 
metastasis [125].
Abbreviations
CAF, cancer associated fi  broblast; Cav, caveolin; CTVT, canine transmissible 
venereal tumor; HIF, hypoxia-inducible factor; LDH, lactate dehydrogenase; 
MCT, monocarboxylate transporter; NF, nuclear factor; PET, position emission 
tomography; ROS, reactive oxygen species; TCA, tricarboxylic acid.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
MPL and his laboratory were supported by grants from the NIH/NCI (R01-
CA-080250; R01-CA-098779; R01-CA-120876; R01-AR-055660), and the Susan 
G Komen Breast Cancer Foundation. FS was supported by grants from the 
WW Smith Charitable Trust, the Breast Cancer Alliance (BCA), and a Research 
Scholar Grant from the American Cancer Society (ACS). RGP was supported 
by grants from the NIH/NCI (R01-CA-70896, R01-CA-75503, R01-CA-86072, 
and R01-CA-107382) and the Dr Ralph and Marian C Falk Medical Research 
Trust. The Kimmel Cancer Center was supported by the NIH/NCI Cancer 
Center Core grant P30-CA-56036 (to RGP). Funds were also contributed by 
the Margaret Q Landenberger Research Foundation (to MPL). This project is 
funded, in part, under a grant with the Pennsylvania Department of Health 
(to MPL). The Department specifi  cally disclaims responsibility for any analyses, 
interpretations or conclusions. This work was also supported, in part, by a 
Centre grant in Manchester from Breakthrough Breast Cancer in the UK (to 
AH) and an Advanced ERC Grant from the European Research Council. Dr MP 
Lisanti would especially like to thank Drs Craig B Thompson, Tak W Mak, Michel 
L Tremblay, and Robert S DiPaola (other participants of the ASBMB/AACR 2011 
Meetings) for their feedback, thoughtful comments, and helpful suggestions. 
This review was recently presented as a lecture at the AACR 2011 Meeting in 
the Educational Session ‘Autophagy and Cell Death’ on 2 April 2011 (Orlando, 
FL). It was also presented as a lecture at the Experimental Biology 2011-ASBMB 
Meeting (Washington, DC) at the session on ‘Metabolism and Cancer’ on 13 
April 2011.
Author details
1The Jeff  erson Stem Cell Biology and Regenerative Medicine Center, 
Philadelphia, PA 19107, USA. 2Departments of Stem Cell Biology and 
Regenerative Medicine, and Cancer Biology, Thomas Jeff  erson University, 
Philadelphia, PA 19107, USA. 3Manchester Breast Centre and Breakthrough 
Breast Cancer Research Unit, Paterson Institute for Cancer Research, 
Manchester, M20 4BX, UK. 4Department of Medical Oncology, Kimmel Cancer 
Center, Thomas Jeff  erson University, Philadelphia, PA 19107, USA.
Published: 8 July 2011
References
1. Warburg  O:  On the origin of cancer cells. Science 1956, 123:309-314.
2. Dang  CV:  PKM2 tyrosine phosphorylation and glutamine metabolism 
signal a diff  erent view of the Warburg eff  ect. Sci Signal 2009, 2:pe75.
3.  Cairns RA, Harris IS, Mak TW: Regulation of cancer cell metabolism. Nat Rev 
Cancer 2011, 11:85-95.
4.  Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB: Brick by brick: 
metabolism and tumor cell growth. Curr Opin Genet Dev 2008, 18:54-61.
5.  Guppy M, Leedman P, Zu X, Russell V: Contribution by diff  erent fuels and 
metabolic pathways to the total ATP turnover of proliferating MCF-7 
breast cancer cells. Biochem J 2002, 364:309-315.
6.  Kallinowski F, Vaupel P, Runkel S, Berg G, Fortmeyer HP, Baessler KH, Wagner K, 
Mueller-Klieser W, Walenta S: Glucose uptake, lactate release, ketone body 
turnover, metabolic micromilieu, and pH distributions in human breast 
cancer xenografts in nude rats. Cancer Res 1988, 48:7264-7272.
7.  Zu XL, Guppy M: Cancer metabolism: facts, fantasy, and fi  ction. Biochem 
Biophys Res Commun 2004, 313:459-465.
8.  Kallinowski F, Schlenger KH, Runkel S, Kloes M, Stohrer M, Okunieff   P, Vaupel P: 
Blood fl  ow, metabolism, cellular microenvironment, and growth rate of 
human tumor xenografts. Cancer Res 1989, 49:3759-3764.
9.  Gstraunthaler G, Seppi T, Pfaller W: Impact of culture conditions, culture 
Figure 6. Lactate treatment of estrogen receptor-positive 
breast cancer cells drives mitochondrial biogenesis, leading to 
poor survival in a subset of luminal A breast cancer patients. 
(a) Lactate-treated (10 mM) MCF7 cells show a signifi  cant increase 
in mitochondrial mass, as visualized by staining with antibodies 
against mitochondrial marker proteins. (b) Lactate-treated (10 mM) 
MCF7 cells were subjected to transcriptional profi  ling (exon-array) 
to generate a gene signature. Interestingly, this lactate-induced 
gene signature predicts poor clinical outcome in estrogen receptor-
positive/luminal A breast cancer patients, which represent nearly 
60 to 70% of cases, and is the most common type of breast cancer. 
Modifi  ed and reproduced with permission from [124].
MCF7 (--) Lactate MCF7 (+) Lactate
(a)
(b)
Sotgia et al. Breast Cancer Research 2011, 13:213
http://breast-cancer-research.com/content/13/4/213
Page 10 of 13media volumes, and glucose content on metabolic properties of renal 
epithelial cell cultures. Are renal cells in tissue culture hypoxic? Cell Physiol 
Biochem 1999, 9:150-172.
10.  Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E: Comparison of 
metabolic pathways between cancer cells and stromal cells in colorectal 
carcinomas: a metabolic survival role for tumor-associated stroma. Cancer 
Res 2006, 66:632-637.
11.  Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-
Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, 
Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD: IDH1 and IDH2 mutations 
in gliomas. N Engl J Med 2009, 360:765-773.
12.  Fogal V, Richardson AD, Karmali PP, Scheffl   er IE, Smith JW, Ruoslahti E: 
Mitochondrial p32 protein is a critical regulator of tumor metabolism via 
maintenance of oxidative phosphorylation. Mol Cell Biol 2010, 
30:1303-1318.
13.  Sheen-Chen SM, Huang CC, Tang RP, Chou FF, Eng HL: Prognostic value of 
signal transducers and activators of transcription 3 in breast cancer. 
Cancer Epidemiol Biomarkers Prev 2008, 17:2286-2290.
14.  Wegrzyn J, Potla R, Chwae YJ, Sepuri NB, Zhang Q, Koeck T, Derecka M, 
Szczepanek K, Szelag M, Gornicka A, Moh A, Moghaddas S, Chen Q, Bobbili S, 
Cichy J, Dulak J, Baker DP, Wolfman A, Stuehr D, Hassan MO, Fu XY, Avadhani 
N, Drake JI, Fawcett P, Lesnefsky EJ, Larner AC: Function of mitochondrial 
Stat3 in cellular respiration. Science 2009, 323:793-797.
15. Reich  NC:  STAT3 revs up the powerhouse. Sci Signal 2009, 2:pe61.
16.  Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, Levy DE: 
Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. 
Science 2009, 324:1713-1716.
17.  Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, 
Kalyanaraman B, Mutlu GM, Budinger GR, Chandel NS: Mitochondrial 
metabolism and ROS generation are essential for Kras-mediated 
tumorigenicity. Proc Natl Acad Sci U S A 2010, 107:8788-8793.
18.  Berridge MV, Tan AS: Eff  ects of mitochondrial gene deletion on 
tumorigenicity of metastatic melanoma: reassessing the Warburg eff  ect. 
Rejuvenation Res 2010, 13:139-141.
19.  Yu M, Shi Y, Wei X, Yang Y, Zhou Y, Hao X, Zhang N, Niu R: Depletion of 
mitochondrial DNA by ethidium bromide treatment inhibits the 
proliferation and tumorigenesis of T47D human breast cancer cells. Toxicol 
Lett 2007, 170:83-93.
20.  Sakamaki T, Casimiro MC, Ju X, Quong AA, Katiyar S, Liu M, Jiao X, Li A, Zhang 
X, Lu Y, Wang C, Byers S, Nicholson R, Link T, Shemluck M, Yang J, Fricke ST, 
Novikoff   PM, Papanikolaou A, Arnold A, Albanese C, Pestell R: Cyclin D1 
determines mitochondrial function in vivo. Mol Cell Biol 2006, 26:5449-5469.
21.  Bostrom P, Soderstrom M, Palokangas T, Vahlberg T, Collan Y, Carpen O, 
Hirsimaki P: Analysis of cyclins A, B1, D1 and E in breast cancer in relation 
to tumour grade and other prognostic factors. BMC Res Notes 2009, 2:140.
22.  Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, 
Van Eyk JE, Mendell JT, Dang CV: c-Myc suppression of miR-23a/b enhances 
mitochondrial glutaminase expression and glutamine metabolism. Nature 
2009, 458:762-765.
23.  Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiff  er HK, Nissim I, 
Daikhin E, Yudkoff   M, McMahon SB, Thompson CB: Myc regulates a 
transcriptional program that stimulates mitochondrial glutaminolysis and 
leads to glutamine addiction. Proc Natl Acad Sci U S A 2008, 
105:18782-18787.
24.  Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, Wilson KF, 
Ambrosio AL, Dias SM, Dang CV, Cerione RA: Targeting mitochondrial 
glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010, 
18:207-219.
25.  Kalluri R, Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer 2006, 6:392-401.
26.  Ronnov-Jessen L, Petersen OW, Bissell MJ: Cellular changes involved in 
conversion of normal to malignant breast: importance of the stromal 
reaction. Physiol Rev 1996, 76:69-125.
27.  Shekhar MP, Pauley R, Heppner G: Host microenvironment in breast cancer 
development: extracellular matrix-stromal cell contribution to neoplastic 
phenotype of epithelial cells in the breast. Breast Cancer Res 2003, 
5:130-135.
28.  Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, 
Carey VJ, Richardson AL, Weinberg RA: Stromal fi  broblasts present in 
invasive human breast carcinomas promote tumor growth and 
angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 
121:335-348.
29.  Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, 
Polyak K, Tubo R, Weinberg RA: Mesenchymal stem cells within tumour 
stroma promote breast cancer metastasis. Nature 2007, 449:557-563.
30.  Wu M, Jung L, Cooper AB, Fleet C, Chen L, Breault L, Clark K, Cai Z, Vincent S, 
Bottega S, Shen Q, Richardson A, Bosenburg M, Naber SP, DePinho RA, 
Kuperwasser C, Robinson MO: Dissecting genetic requirements of human 
breast tumorigenesis in a tissue transgenic model of human breast cancer 
in mice. Proc Natl Acad Sci U S A 2009, 106:7022-7027.
31.  Howell A, Landberg G, Bergh J: Breast tumour stroma is a prognostic 
indicator and target for therapy. Breast Cancer Res 2009, 11 Suppl 3:S16.
32.  Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, 
Omeroglu G, Meterissian S, Omeroglu A, Hallett M, Park M: Stromal gene 
expression predicts clinical outcome in breast cancer. Nat Med 2008, 
14:518-527.
33.  Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC: Gene expression 
profi  ling of the tumor microenvironment during breast cancer 
progression. Breast Cancer Res 2009, 11:R7.
34.  Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, 
Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni 
L, Symmans WF, Pusztai L: Molecular anatomy of breast cancer stroma and 
its prognostic value in estrogen receptor-positive and -negative cancers. 
J Clin Oncol 2010, 28:4316-4323.
35.  Witkiewicz AK, Casimiro MC, Dasgupta A, Mercier I, Wang C, Bonuccelli G, 
Jasmin JF, Frank PG, Pestell RG, Kleer CG, Sotgia F, Lisanti MP: Towards a new 
“stromal-based” classifi  cation system for human breast cancer prognosis 
and therapy. Cell Cycle 2009, 8:1654-1658.
36.  Sloan EK, Ciocca DR, Pouliot N, Natoli A, Restall C, Henderson MA, Fanelli MA, 
Cuello-Carrion FD, Gago FE, Anderson RL: Stromal cell expression of 
caveolin-1 predicts outcome in breast cancer. Am J Pathol 2009, 
174:2035-2043.
37.  Witkiewicz AK, Dasgupta A, Sammons S, Er O, Potoczek MB, Guiles F, Sotgia F, 
Brody JR, Mitchell EP, Lisanti MP: Loss of stromal caveolin-1 expression 
predicts poor clinical outcome in triple negative and basal-like breast 
cancers. Cancer Biol Ther 2010, 10:135-143.
38.  Di Vizio D, Morello M, Sotgia F, Pestell RG, Freeman MR, Lisanti MP: An 
absence of stromal caveolin-1 is associated with advanced prostate 
cancer, metastatic disease and epithelial Akt activation. Cell Cycle 2009, 
8:2420-2424.
39.  Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz 
AK, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, Pestell RG, Martinez-
Outschoorn UE, Sotgia F, Lisanti MP: The reverse Warburg eff  ect: aerobic 
glycolysis in cancer associated fi  broblasts and the tumor stroma. Cell Cycle 
2009, 8:3984-4001.
40.  Bosch M, Marí M, Herms A, Fernández A, Fajardo A, Kassan A, Giralt A, Colell A, 
Balgoma D, Barbero E, González-Moreno E, Matias N, Tebar F, Balsinde J, 
Camps M, Enrich C, Gross SP, García-Ruiz C, Pérez-Navarro E, Fernández-Checa 
JC, Pol A: Caveolin-1 defi  ciency causes cholesterol-dependent 
mitochondrial dysfunction and apoptotic susceptibility. Curr Biol 2011, 
21:681-686.
41.  Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, Chiavarina B, Pavlides S, 
Wang C, Whitaker-Menezes D, Daumer KM, Lin Z, Witkiewicz AK, Flomenberg 
N, Howell A, Pestell RG, Knudsen ES, Sotgia F, Lisanti MP: Oxidative stress in 
cancer associated fi  broblasts drives tumor-stroma co-evolution: A new 
paradigm for understanding tumor metabolism, the fi  eld eff  ect and 
genomic instability in cancer cells. Cell Cycle 2010, 9:3256-3276.
42.  Mueller-Lisse UG, Mueller-Lisse UL: Imaging of advanced renal cell 
carcinoma. World J Urol 2010, 28:253-261.
43.  Avril N, Dambha F, Murray I, Shamash J, Powles T, Sahdev A: The clinical 
advances of fl  uorine-2-D-deoxyglucose--positron emission tomography/
computed tomography in urological cancers. Int J Urol 2010, 17:501-511.
44.  Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh 
FM, et al.: Mutations of the VHL tumour suppressor gene in renal 
carcinoma. Nat Genet 1994, 7:85-90.
45.  Cowey CL, Rathmell WK: VHL gene mutations in renal cell carcinoma: role 
as a biomarker of disease outcome and drug effi   cacy. Curr Oncol Rep 2009, 
11:94-101.
46.  Tanimoto K, Makino Y, Pereira T, Poellinger L: Mechanism of regulation of the 
hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor 
suppressor protein. EMBO J 2000, 19:4298-4309.
47.  Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW: 
Activation of HIF1alpha ubiquitination by a reconstituted von 
Sotgia et al. Breast Cancer Research 2011, 13:213
http://breast-cancer-research.com/content/13/4/213
Page 11 of 13Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci U S A 
2000, 97:10430-10435.
48.  Ohh M, Park CW, Ivan M, Hoff  man MA, Kim TY, Huang LE, Pavletich N, Chau V, 
Kaelin WG: Ubiquitination of hypoxia-inducible factor requires direct 
binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 
2000, 2:423-427.
49.  Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I, Ben-Barak 
A, Ben-Arie Y, Bar-Shalom R, Israel O: (18)F-FDG avidity in lymphoma 
readdressed: a study of 766 patients. J Nucl Med 2010, 51:25-30.
50.  Aldinucci D, Gloghini A, Pinto A, De Filippi R, Carbone A: The classical 
Hodgkin’s lymphoma microenvironment and its role in promoting tumour 
growth and immune escape. J Pathol 2010, 221:248-263.
51.  Groves AM, Win T, Screaton NJ, Berovic M, Endozo R, Booth H, Kayani I, 
Menezes LJ, Dickson JC, Ell PJ: Idiopathic pulmonary fi  brosis and diff  use 
parenchymal lung disease: implications from initial experience with 18F-
FDG PET/CT. J Nucl Med 2009, 50:538-545.
52.  Su YQ, Sugiura K, Eppig JJ: Mouse oocyte control of granulosa cell 
development and function: paracrine regulation of cumulus cell 
metabolism. Semin Reprod Med 2009, 27:32-42.
53.  Sugiura K, Su YQ, Diaz FJ, Pangas SA, Sharma S, Wigglesworth K, O’Brien MJ, 
Matzuk MM, Shimasaki S, Eppig JJ: Oocyte-derived BMP15 and FGFs 
cooperate to promote glycolysis in cumulus cells. Development 2007, 
134:2593-2603.
54.  Biggers JD, Whittingham DG, Donahue RP: The pattern of energy 
metabolism in the mouse oocyte and zygote. Proc Natl Acad Sci U S A 1967, 
58:560-567.
55. Brinster  RL:  Studies on the development of mouse embryos in vitro. Ii. The 
eff  ect of energy source. J Exp Zool 1965, 158:59-68.
56.  Sugiura K, Pendola FL, Eppig JJ: Oocyte control of metabolic cooperativity 
between oocytes and companion granulosa cells: energy metabolism. 
Dev Biol 2005, 279:20-30.
57. Brinster  RL:  Oxidation of pyruvate and glucose by oocytes of the mouse 
and rhesus monkey. J Reprod Fertil 1971, 24:187-191.
58.  Colonna R, Mangia F: Mechanisms of amino acid uptake in cumulus-
enclosed mouse oocytes. Biol Reprod 1983, 28:797-803.
59.  Su YQ, Sugiura K, Wigglesworth K, O’Brien MJ, Aff  ourtit JP, Pangas SA, Matzuk 
MM, Eppig JJ: Oocyte regulation of metabolic cooperativity between 
mouse cumulus cells and oocytes: BMP15 and GDF9 control cholesterol 
biosynthesis in cumulus cells. Development 2008, 135:111-121.
60.  Tsacopoulos M, Magistretti PJ: Metabolic coupling between glia and 
neurons. J Neurosci 1996, 16:877-885.
61.  Magistretti PJ, Pellerin L: Cellular mechanisms of brain energy metabolism. 
Relevance to functional brain imaging and to neurodegenerative 
disorders. Ann N Y Acad Sci 1996, 777:380-387.
62.  Bittar PG, Charnay Y, Pellerin L, Bouras C, Magistretti PJ: Selective distribution 
of lactate dehydrogenase isoenzymes in neurons and astrocytes of 
human brain. J Cereb Blood Flow Metab 1996, 16:1079-1089.
63.  Laughton JD, Bittar P, Charnay Y, Pellerin L, Kovari E, Magistretti PJ, Bouras C: 
Metabolic compartmentalization in the human cortex and hippocampus: 
evidence for a cell- and region-specifi  c localization of lactate 
dehydrogenase 5 and pyruvate dehydrogenase. BMC Neurosci 2007, 8:35.
64.  Connett RJ, Gayeski TE, Honig CR: Lactate accumulation in fully aerobic, 
working, dog gracilis muscle. Am J Physiol 1984, 246:H120-128.
65.  McCullagh KJ, Poole RC, Halestrap AP, Tipton KF, O’Brien M, Bonen A: Chronic 
electrical stimulation increases MCT1 and lactate uptake in red and white 
skeletal muscle. Am J Physiol 1997, 273:E239-246.
66. Brooks  GA:  The lactate shuttle during exercise and recovery. Med Sci Sports 
Exerc 1986, 18:360-368.
67.  Whitaker-Menezes D, Martinez-Outschoorn UE, Lin Z, Ertel A, Flomenberg N, 
Witkiewicz AK, Birbe RC, Howell A, Pavlides S, Gandara R, Pestell RG, Sotgia F, 
Philp NJ, Lisanti MP: Evidence for a stromal-epithelial ‘lactate shuttle’ in 
human tumors: MCT4 is a marker of oxidative stress in cancer-associated 
fi  broblasts. Cell Cycle 2011, 10:1772-1783.
68.  Toullec A, Gerald D, Despouy G, Bourachot B, Cardon M, Lefort S, Richardson 
M, Rigaill G, Parrini MC, Lucchesi C, Bellanger D, Stern MH, Dubois T, Sastre-
Garau X, Delattre O, Vincent-Salomon A, Mechta-Grigoriou F: Oxidative stress 
promotes myofi  broblast diff  erentiation and tumour spreading. EMBO Mol 
Med 2010, 2:211-230.
69.  Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, Daumer KM, 
Milliman JN, Chiavarina B, Migneco G, Witkiewicz AK, Martinez-Cantarin MP, 
Flomenberg N, Howell A, Pestell RG, Lisanti MP, Sotgia F: Tumor cells induce 
the cancer associated fi  broblast phenotype via caveolin-1 degradation: 
Implications for breast cancer and DCIS therapy with autophagy 
inhibitors. Cell Cycle 2010, 9:2423-2433.
70.  Ramanathan A, Wang C, Schreiber SL: Perturbational profi  ling of a cell-line 
model of tumorigenesis by using metabolic measurements. Proc Natl Acad 
Sci U S A 2005, 102:5992-5997.
71.  Migneco G, Whitaker-Menezes D, Chiavarina B, Castello-Cros R, Pavlides S, 
Pestell RG, Fatatis A, Flomenberg N, Tsirigos A, Howell A, Martinez-
Outschoorn UE, Sotgia F, Lisanti MP: Glycolytic cancer associated fi  broblasts 
promote breast cancer tumor growth, without a measurable increase in 
angiogenesis: Evidence for stromal-epithelial metabolic coupling. Cell 
Cycle 2010, 9:2412-2422.
72.  Sung SY, Hsieh CL, Law A, Zhau HE, Pathak S, Multani AS, Lim S, Coleman IM, 
Wu LC, Figg WD, Dahut WL, Nelson P, Lee JK, Amin MB, Lyles R, Johnstone PA, 
Marshall FF, Chung LW: Coevolution of prostate cancer and bone stroma in 
three-dimensional coculture: implications for cancer growth and 
metastasis. Cancer Res 2008, 68:9996-10003.
73.  Lisanti MP, Martinez-Outschoorn UE, Chiavarina B, Pavlides S, Whitaker-
Menezes D, Tsirigos A, Witkiewicz A, Lin Z, Balliet R, Howell A, Sotgia F: 
Understanding the “lethal” drivers of tumor-stroma co-evolution: 
emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy 
in the tumor micro-environment. Cancer Biol Ther 2011, 10:537-542.
74.  Pavlides S, Tsirigos A, Migneco G, Whitaker-Menezes D, Chiavarina B, 
Flomenberg N, Frank PG, Casimiro MC, Wang C, Pestell RG, Martinez-
Outschoorn UE, Howell A, Sotgia F, Lisanti MP: The autophagic tumor 
stroma model of cancer: Role of oxidative stress and ketone production in 
fueling tumor cell metabolism. Cell Cycle 2010, 9:3485-3505.
75.  Azad MB, Gibson SB: Role of BNIP3 in proliferation and hypoxia-induced 
autophagy: implications for personalized cancer therapies. Ann N Y Acad 
Sci 2010, 1210:8-16.
76.  Kume S, Uzu T, Horiike K, Chin-Kanasaki M, Isshiki K, Araki S, Sugimoto T, 
Haneda M, Kashiwagi A, Koya D: Calorie restriction enhances cell 
adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy 
in mouse aged kidney. J Clin Invest 2010, 120:1043-1055.
77.  Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM: 
Hypoxia promotes invasive growth by transcriptional activation of the 
met protooncogene. Cancer Cell 2003, 3:347-361.
78.  Martinez-Outschoorn UE, Trimmer C, Lin Z, Whitaker-Menezes D, Chiavarina 
B, Zhou J, Wang C, Pavlides S, Martinez-Cantarin MP, Capozza F, Witkiewicz AK, 
Flomenberg N, Howell A, Pestell RG, Caro J, Lisanti MP, Sotgia F: Autophagy in 
cancer associated fi  broblasts promotes tumor cell survival: Role of 
hypoxia, HIF1 induction and NFkappaB activation in the tumor stromal 
microenvironment. Cell Cycle 2010, 9:3515-3533.
79.  Chiavarina B, Whitaker-Menezes D, Migneco G, Martinez-Outschoorn UE, 
Pavlides S, Howell A, Tanowitz HB, Casimiro MC, Wang C, Pestell RG, 
Grieshaber P, Caro J, Sotgia F, Lisanti MP: HIF1-alpha functions as a tumor 
promoter in cancer associated fi  broblasts, and as a tumor suppressor in 
breast cancer cells: Autophagy drives compartment-specifi  c oncogenesis. 
Cell Cycle 2010, 9:3534-3551.
80.  Nomura H, Uzawa K, Yamano Y, Fushimi K, Ishigami T, Kouzu Y, Koike H, Siiba 
M, Bukawa H, Yokoe H, Kubosawa H, Tanzawa H: Overexpression and altered 
subcellular localization of autophagy-related 16-like 1 in human oral 
squamous-cell carcinoma: correlation with lymphovascular invasion and 
lymph-node metastasis. Hum Pathol 2009, 40:83-91.
81.  Nadji M, Fresno M, Nassiri M, Conner G, Herrero A, Morales AR: Cathepsin D in 
host stromal cells, but not in tumor cells, is associated with aggressive 
behavior in node-negative breast cancer. Hum Pathol 1996, 27:890-895.
82.  Kleer CG, Bloushtain-Qimron N, Chen YH, Carrasco D, Hu M, Yao J, Kraeft SK, 
Collins LC, Sabel MS, Argani P, Gelman R, Schnitt SJ, Krop IE, Polyak K: 
Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor 
progression. Clin Cancer Res 2008, 14:5357-5367.
83.  Levine B, Kroemer G: Autophagy in the pathogenesis of disease. Cell 2008, 
132:27-42.
84.  Denkert C, Budczies J, Kind T, Weichert W, Tablack P, Sehouli J, Niesporek S, 
Konsgen D, Dietel M, Fiehn O: Mass spectrometry-based metabolic 
profi  ling reveals diff  erent metabolite patterns in invasive ovarian 
carcinomas and ovarian borderline tumors. Cancer Res 2006, 
66:10795-10804.
85.  Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, Kinoshita 
T, Saito N, Ochiai A, Tomita M, Esumi H, Soga T: Quantitative metabolome 
profi  ling of colon and stomach cancer microenvironment by capillary 
Sotgia et al. Breast Cancer Research 2011, 13:213
http://breast-cancer-research.com/content/13/4/213
Page 12 of 13electrophoresis time-of-fl  ight mass spectrometry. Cancer Res 2009, 
69:4918-4925.
86.  Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, 
Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao 
X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster 
JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profi  les 
delineate potential role for sarcosine in prostate cancer progression. 
Nature 2009, 457:910-914.
87.  Eisenberg-Lerner A, Kimchi A: The paradox of autophagy and its 
implication in cancer etiology and therapy. Apoptosis 2009, 14:376-391.
88.  Maclean KH, Dorsey FC, Cleveland JL, Kastan MB: Targeting lysosomal 
degradation induces p53-dependent cell death and prevents cancer in 
mouse models of lymphomagenesis. J Clin Invest 2008, 118:79-88.
89.  Sparks CA, Guertin DA: Targeting mTOR: prospects for mTOR complex 2 
inhibitors in cancer therapy. Oncogene 2010, 29:3733-3744.
90.  Loges S, Mazzone M, Hohensinner P, Carmeliet P: Silencing or fueling 
metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 
2009, 15:167-170.
91.  Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, 
Bergers G, Hanahan D, Casanovas O: Antiangiogenic therapy elicits 
malignant progression of tumors to increased local invasion and distant 
metastasis. Cancer Cell 2009, 15:220-231.
92.  Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS: 
Accelerated metastasis after short-term treatment with a potent inhibitor 
of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
93. Blagosklonny  MV:  Antiangiogenic therapy and tumor progression. Cancer 
Cell 2004, 5:13-17.
94. Tisdale  MJ:  Cancer cachexia. Curr Opin Gastroenterol 2010, 26:146-151.
95. Holmes  S:  A diffi   cult clinical problem: diagnosis, impact and clinical 
management of cachexia in palliative care. Int J Palliat Nurs 2009, 15:320, 
322-326.
96.  McClung JM, Judge AR, Powers SK, Yan Z: p38 MAPK links oxidative stress to 
autophagy-related gene expression in cachectic muscle wasting. Am J 
Physiol Cell Physiol 2010, 298:C542-549.
97.  Asp ML, Tian M, Wendel AA, Belury MA: Evidence for the contribution of 
insulin resistance to the development of cachexia in tumor-bearing mice. 
Int J Cancer 2010, 126:756-763.
98.  Witkiewicz AK, Kline J, Queenan M, Brody JR, Tsirigos A, Pavlides S, Sotgia F, 
Lisanti MP: Molecular profi  ling of a lethal tumor microenvironment, as 
defi  ned by stromal caveolin-1 status in breast cancers. Cell Cycle 2011, 
10:1794-1809.
99.  Martinez-Outschoorn UE, Whitaker-Menezes D, Lin Z, Flomenberg N, Howell 
A, Pestell RG, Lisanti MP, Sotgia F: Cytokine production and infl  ammation 
drive autophagy in the tumor microenvironment: Role of stromal 
caveolin-1 as a key regulator. Cell Cycle 2011, 10:1784-1793.
100. Dang  CV:  Glutaminolysis: supplying carbon or nitrogen or both for cancer 
cells? Cell Cycle 2010, 9:3884-3886.
101.  Wise DR, Thompson CB: Glutamine addiction: a new therapeutic target in 
cancer. Trends Biochem Sci 2010, 35:427-433.
102.  Dang CV, Le A, Gao P: MYC-induced cancer cell energy metabolism and 
therapeutic opportunities. Clin Cancer Res 2009, 15:6479-6483.
103.  Kaadige MR, Looper RE, Kamalanaadhan S, Ayer DE: Glutamine-dependent 
anapleurosis dictates glucose uptake and cell growth by regulating 
MondoA transcriptional activity. Proc Natl Acad Sci U S A 2009, 
106:14878-14883.
104.  Eng CH, Abraham RT: Glutaminolysis yields a metabolic by-product that 
stimulates autophagy. Autophagy 2010, 6:968-970.
105.  Eng CH, Yu K, Lucas J, White E, Abraham RT: Ammonia derived from 
glutaminolysis is a diff  usible regulator of autophagy. Sci Signal 2010, 3:ra31.
106.  Marino G, Kroemer G: Ammonia: a diff  usible factor released by proliferating 
cells that induces autophagy. Sci Signal 2010, 3:pe19.
107.  Dey S, Guha M, Alam A, Goyal M, Bindu S, Pal C, Maity P, Mitra K, 
Bandyopadhyay U: Malarial infection develops mitochondrial pathology 
and mitochondrial oxidative stress to promote hepatocyte apoptosis. Free 
Radic Biol Med 2009, 46:271-281.
108.  Postma NS, Mommers EC, Eling WM, Zuidema J: Oxidative stress in malaria; 
implications for prevention and therapy. Pharm World Sci 1996, 18:121-129.
109.  Siddiqi NJ, Alhomida AS: Status of hepatic oxidative stress and antioxidant 
defense systems during chloroquine treatment of Plasmodium yoelii 
nigeriensis infected mice. In Vivo 1999, 13:547-550.
110.  Solomon VR, Lee H: Chloroquine and its analogs: a new promise of an old 
drug for eff  ective and safe cancer therapies. Eur J Pharmacol 2009, 
625:220-233.
111. Murchison  EP:  Clonally transmissible cancers in dogs and Tasmanian devils. 
Oncogene 2008, 27 Suppl 2:S19-30.
112.  Thomas R, Rebbeck C, Leroi AM, Burt A, Breen M: Extensive conservation of 
genomic imbalances in canine transmissible venereal tumors (CTVT) 
detected by microarray-based CGH analysis. Chromosome Res 2009, 
17:927-934.
113.  McCallum H, Jones M, Hawkins C, Hamede R, Lachish S, Sinn DL, Beeton N, 
Lazenby B: Transmission dynamics of Tasmanian devil facial tumor disease 
may lead to disease-induced extinction. Ecology 2009, 90:3379-3392.
114.  Kreiss A, Tovar C, Obendorf DL, Dun K, Woods GM: A murine xenograft 
model for a transmissible cancer in Tasmanian devils. Vet Pathol 2011, 
48:475-481.
115.  Copper HL, Mackay CM, Banfi  eld WG: Chromosome studies of a contagious 
reticulum cell sarcoma of the Syrian hamster. J Natl Cancer Inst 1964, 
33:691-706.
116.  Banfi  eld WG, Woke PA, Mackay CM, Cooper HL: Mosquito transmission of a 
reticulum cell sarcoma of hamsters. Science 1965, 148:1239-1240.
117.  Gartner HV, Seidl C, Luckenbach C, Schumm G, Seifried E, Ritter H, Bultmann 
B: Genetic analysis of a sarcoma accidentally transplanted from a patient 
to a surgeon. N Engl J Med 1996, 335:1494-1496.
118.  Rebbeck CA, Thomas R, Breen M, Leroi AM, Burt A: Origins and evolution of a 
transmissible cancer. Evolution 2009, 63:2340-2349.
119.  Rebbeck CA, Leroi AM, Burt A: Mitochondrial capture by a transmissible 
cancer. Science 2011, 331:303.
120. Villanueva  T:  Metabolism: the mitochondria that wag the dog. Nat Rev 
Cancer 2011, 11:155.
121.  Stettner N, Brenner O, Eilam R, Harmelin A: Pegylated liposomal doxorubicin 
as a chemotherapeutic agent for treatment of canine transmissible 
venereal tumor in murine models. J Vet Med Sci 2005, 67:1133-1139.
122.  Spees JL, Olson SD, Whitney MJ, Prockop DJ: Mitochondrial transfer 
between cells can rescue aerobic respiration. Proc Natl Acad Sci U S A 2006, 
103:1283-1288.
123.  Chen EI, Hewel J, Krueger JS, Tiraby C, Weber MR, Kralli A, Becker K, Yates JR 
3rd, Felding-Habermann B: Adaptation of energy metabolism in breast 
cancer brain metastases. Cancer Res 2007, 67:1472-1486.
124.  Martinez-Outschoorn UE, Prisco M, Ertel A, Tsirigos A, Lin Z, Pavlides S, Wang 
C, Flomenberg N, Knudsen ES, Howell A, Pestell RG, Sotgia F, Lisanti MP: 
Ketones and lactate increase cancer cell “stemness,” driving recurrence, 
metastasis, and poor clinical outcome in breast cancer: Achieving 
personalized medicine via Metabolo-Genomics. Cell Cycle 2011, 
10:1271-1286.
125.  Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell RG, 
Chiavarina B, Frank PG, Flomenberg N, Howell A, Martinez-Outschoorn UE, 
Sotgia F, Lisanti MP: Ketones and lactate “fuel” tumor growth and 
metastasis: Evidence that epithelial cancer cells use oxidative 
mitochondrial metabolism. Cell Cycle 2010, 9:3506-3514.
doi:10.1186/bcr2892
Cite this article as: Sotgia F, et al.: Understanding the Warburg eff  ect and 
the prognostic value of stromal caveolin-1 as a marker of a lethal tumor 
microenvironment. Breast Cancer Research 2011, 13:213.
Sotgia et al. Breast Cancer Research 2011, 13:213
http://breast-cancer-research.com/content/13/4/213
Page 13 of 13